参考文献
［1］World Health Organization. World health statistics［OL］.［2019-06-15］. https://www.who.int/gho/world-health-statistics
［2］SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2019［J］. CA Cancer J Clin, 2019, 69（1）: 7-34.
［3］国家统计局.2018中国统计年鉴［M］.北京：中国统计出版社，2018.
［4］BANG Y J, VAN CUTSEM E, FEYEREISLOVA A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer（ToGA）: a phase 3, open-label, randomised controlled trial［J］. Lancet, 2010, 376（9742）: 687-697.
［5］TOL J, KOOPMAN M, CATS A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer［J］. N Engl J Med, 2009, 360（6）: 563-572.
［6］DEMETRI G D, VON MEHREN M, BLANKE C D, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors［J］. N Engl J Med, 2002, 347（7）: 472-480.
［7］LLOVET J M, RICCI S, MAZZAFERRO V, et al. Sorafenib in advanced hepatocellular carcinoma［J］. N Engl J Med, 2008, 359（4）: 378-390.
［8］EL-KHOUEIRY A B, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma（CheckMate 040）: an open-label, non-comparative, phase 1/2 dose escalation and expansion trial［J］. Lancet, 2017, 389（10088）: 2492-2502.
［9］KATO K, SHAH MA, ENZINGER P, et al. KEYNOTE-590: phase Ⅲ study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer［J］. Future Oncol, 2019, 15（10）: 1057-1066.
［10］FUCHS C S, DOI T, JANG R W, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial［J］. JAMA Oncol, 2018, 4（5）: e180013.
［11］LE D T, URAM J N, WANG H, et al. PD-1 blockade in tumors with mismatch-repair deficiency［J］. N Engl J Med, 2015, 372（26）: 2509-2520.
［12］GOEY K K H, ELIAS S G, VAN TINTEREN H, et al. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study［J］. Ann Oncol, 2017, 28（9）: 2128-2134.
［13］HAANEN J, CARBONNEL F, ROBERT C, et al. Management of toxicities from immunotherapy. ESMO Clinical Practice Guidelines for diagnosis, treatment and followup［OL］.［2019-06-15］. https://www.esmo.org/content/download/151567/2718664/file/Clinical-Practice-Guidelines-Slideset-Toxicities-Immunotherapy.pdf.
［14］ERNSTOFF M S, PUZANOV I, ROBERT C, et al. SITC’s Guide to Managing Immunotherapy Toxicity［OL］.［2019-06-10］. https://www.sitcancer.org/research/sitcs-guidemanaging-immunotherapy-toxicity.
［15］BRAHMER J R, LACCHETTI C, SCHNEIDER B J, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline［J］. J Clin Oncol, 2018, 36（17）: 1714-1768.
［16］National Comprehensive Cancer Network. NCCN guidelines［OL］.［2019-06-15］https://www.nccn.org/professionals/physician_gls/default.aspx#immunotherapy
［17］CORTINOVIS D, BAJETTA E, DI BARTOLOMEO M, et al. Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer［J］. Tumori, 2004, 90（2）: 186-191.
［18］LI J, QIN S, XU J, et al. Randomized, double-blind, placebocontrolled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction［J］. J Clin Oncol, 2016, 34（13）: 1448-1454.
［19］LI J, QIN S, XU R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer（CONCUR）: a randomized, double-blind, placebo-controlled, phase 3 trial［J］. Lancet Oncol, 2015, 16（6）: 619-629.
［20］DEMETRI G D, REICHARDT P, KANG Y K, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib（GRID）: an international, multicentre, randomised, placebo-controlled, phase 3 trial［J］. Lancet, 2013, 381（9863）: 295-302.
［21］BRUIX J, QIN S, MERLE P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment（RESORCE）: a randomised, double-blind, placebocontrolled, phase 3 trial［J］. Lancet, 2017, 389（10064）: 56-66.
［22］KUDO M, FINN RS, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial［J］. Lancet, 2018, 391（10126）: 1163-1173.
［23］LI J, QIN S, XU R H, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial［J］. JAMA, 2018, 319（24）: 2486-2496.